Category: ACN Newswire

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Organised by the Hong Kong Trade Development Council (HKTDC), the world’s largest one-stop jewellery marketplace will return in early March under its proven “Two Shows, Two Venues” format. The 12th Hong Kong International Diamond, Gem & Pearl Show will take place from 2 to 6 March at AsiaWorld-Expo and will feature a wide range of jewellery raw materials. Also, the 42nd Hong Kong International Jewellery Show will be held from 4 to 8 March at the Hong Kong Convention and Exhibition Centre and will showcase finished jewellery pieces.Jenny Koo, Deputy Executive Director of the HKTDC, said: “This year’s twin jewellery shows bring together some 4,000 exhibitors from over 40 countries and regions, with 70% coming from outside Hong Kong. Exhibitor participation from Brazil, United Arab Emirates and India has expanded, and Uzbekistan joins for the first time. The HKTDC presents the world’s largest one-stop jewellery marketplace to highlight Hong Kong’s status as an international trade capital and jewellery sourcing hub.”In reviewing the global jewellery market, Hong Kong’s export volume of premium jewellery to ASEAN recorded a 51% increase, while exports to the United Kingdom, Australia and Switzerland grew year-on-year by 36%, 28% and 10% respectively.Over 40 themed pavilions, including a new Hard Pure Gold PavilionThe twin shows attract strong global industry support, with exhibitors participating from over 40 regional and industry pavilions. Participating regions include Chinese Mainland, Taiwan, India, Israel, Korea, Myanmar, Singapore, Sri Lanka, Thailand, Uzbekistan, Belgium, Germany, Italy, Spain, Türkiye, Brazil, Colombia, Mexico and the United States, etc.The World Gold Council debuts the Hard Pure Gold Pavilion, featuring a total of 11 exhibitors from Chinese Mainland, showcasing innovative gold craftsmanship to the global market. The pavilion aims to leverage the fairs as a springboard for international expansion.The Hong Kong Watch Manufacturers Association Ltd will participate as a pavilion for the first time, while the Zhushan Turquoise pavilion from Hubei will also make its debut. Other returning participants include the Tanzanite Foundation, the International Colored Gemstone Association (ICA), the Asia Pacific Creator Association, and the Asia Jewellery Culture Design and Crafts Association. The Hong Kong Jewellery & Jade Manufacturers Association will once again join forces with the Italian Exhibition Group (IEG) to present advanced jewellery manufacturing equipment and technologies.International brands in the spotlightThe Hall of Fame at the Hong Kong International Jewellery Show makes a highly anticipated return this year with more than 40% expansion in scale. It will welcome renowned international jewellery brands and help enhance global brand exposure. Turkish diamond jewellery brand Zen Diamond (Booth: CEC 3B-C12) presents diamond ring collections featuring exquisite cutting techniques. At the Hall of Extraordinary, Hong Kong exhibitor Continental Diamond Company (Booth: CEC GH-C07) showcases an 18K white and rose gold ring set with blue and light pink diamonds. Another Hong Kong exhibitor, Unique Brilliant Ltd (Booth: CEC GH-C13), unveils a necklace and earring set, the rubies display the coveted “pigeon blood red” colour.Oriental Aesthetics showcases cultural heritage craftsmanshipThis year’s shows will feature numerous jewellery pieces inspired by Asian culture and heritage. Chinese Mainland exhibitor, Guangdong JIABAO Pavilion Jewellery (Hong Kong) Company Ltd (Booth: CEC GH-A16) presents an 18K gold, handmade filigree butterfly brooch, made with national intangible heritage craft, with each piece taking over four months to complete. Another Chinese Mainland exhibitor, Shenzhen Meifei Precious Metals Co Ltd (Booth: CEC 3E-E02), brings a “Palatial Modern Chinese Style” jewellery series incorporating six traditional gold techniques, blending heritage craftsmanship with modern jewellery design.In recent years, hard pure gold technology has gained strong momentum in Chinese Mainland. Its high purity and enhanced hardness enable lighter, more durable designs with modern aesthetics. A seminar organised by the World Gold Council will examine the latest developments in the global gold market and hard pure gold technology.During the fairs, a series of events spotlighting Oriental aesthetics in jewellery will be staged. Hong Kong International Fashion Chuk Kam Jewellery Design Competition 2026, organised by the Jewellers’ and Goldsmiths’ Association of Hong Kong Limited, encourages designers to create commercially viable and culturally rich gold jewellery for young consumer markets in ASEAN and the Middle East. Its award presentation ceremony will be held during the fairs.In addition, the inaugural International Fei Cui Jewellery Design Competition 2026, organised by the Hong Kong Jade Association, will also host its awards presentation during the fairs.Creative design sets the trendInnovative and trend-driven products help the industry stand out. Austy Lee Company Ltd (Booth: CEC 1E-F32) introduces bangles inspired by zebra patterns for the Year of the Horse. Designer Galleria welcomes new exhibitor Zheng Hong Collective (Booth: CEC 1CON-067A), featuring a brooch whose movable wings and tail sway with the wearer.The 27th Hong Kong Jewellery Design Competition, themed “Pure Elegance – Natural Beauty”, returns to nurture creative talent. Local students and industry professionals interpret the beauty of nature and their design stories through their creations, highlighting the diverse facets of jewellery design. Winning designs will be announced during the fairs.Rare treasures dazzle across both showsAs always, the twin shows offer buyers an outstanding selection of antique and rare jewellery. At the Hong Kong International Jewellery Show, Hong Kong exhibitor Baroque Antique & Jewellery Limited (Booth: CEC CH-F13) presents a 1970s Buccellati pink sapphire suite, while World Coins Co., Ltd. (Booth: CEC CH-N12) showcases a 19th-century Italian bi-colour enamel diamond piece preserved in its original box for over 100 years. At the Hong Kong International Diamond, Gem & Pearl Show, German exhibitor Caram e.K. (Booth: AWE 8-F05) features an 18.98-carat AGL-certified natural pink sapphire, while Canadian exhibitor Korite Ammolite Ltd. (Booth: AWE 8-F35) displays an 18K gold AA-grade ammolite and diamond necklace.The Hong Kong International Jewellery Show will also host a seminar titled “The Origins of Style: Tracing the Imprint of Time and Craftsmanship.” This seminar will invite British historian and jewellery authority Dr. Jack Ogden to speak. He will provide an in-depth analysis of the evolution of jewellery craftsmanship and changes in aesthetic tastes across different eras.Over 20 forums on hot topics including AI and digital marketingMore than 20 seminars and networking sessions will be held, covering industry trends, digital marketing and jewellery technologies. A session will examine how artificial intelligence moves from design to commercialisation to drive the development of the jewellery industry. There will also be seminars where influencers share how to leverage e-commerce platforms to enhance jewellery brand visibility, boost sales, and share practical experience, to help the industry accelerate the integration and synergy between online and offline channels.Business opportunities and industry exchangeThe exhibition attracts major international jewellery retail chains, as well as high-end, affordable luxury, and designer jewellery brands from around the world for sourcing. It creates business opportunities for both buyers and sellers while fostering industry exchange.The HKTDC has partnered with the Hong Kong Tourism Board and local enterprises to provide exclusive buyer privileges. These offers include dining, air tickets, and hotels, enabling buyers to enjoy Hong Kong’s unique charm while attending the fairs. The HKTDC will arrange free shuttle bus services between AsiaWorld-Expo and urban areas (including the Hong Kong Convention and Exhibition Centre in Wan Chai). For details, please refer to the fair’s official website.Combining online and offline services to facilitate sourcingThe shows use the EXHIBITION+ hybrid format. In addition to on-site procurement, the HKTDC’s AI-powered “Click2Match” will provide online business-matching for exhibitors and buyers from 23 February to 13 March. On-site buyers can use "Scan2Match" to scan exhibitors’ QR codes and continue discussions with exhibitors online during or after the show. To ease the buyer admission process, the HKTDC Marketplace App and the official websites of the two shows provide online verification functions. Buyers need only register through these platforms and upload a photo and valid identification to obtain a verified eBadge for direct entry, greatly reducing queuing times for onsite registration and verification and enhancing sourcing efficiency.Photo download: https://bit.ly/4ayrcAoAttending the press conference to introduce the twin jewellery shows today (5 February): Jenny Koo, HKTDC Deputy Executive Director (centre), Winston Chow, Chairman, HKTDC Jewellery Advisory Committee (left) and Kent Wong, Chairman, HKTDC Hong Kong International Jewellery Show and HKTDC Hong Kong International Diamond, Gem and Pearl Show Fair Organising Committee (right)Jenny Koo (front row, third left) took a group photo with members of the organising committee of the HKTDC Hong Kong International Jewellery Show and the Hong Kong International Diamond, Gem and Pearl Show, joined by celebrity guestArtist Hera Chan (third right) led a group of models to exhibit exquisite jewellery pieces from the showsArtist Hera Chan wore a natural Myanmar jadeite set presented by exhibitor On Tung Company. The exquisite ensemble featured a translucent emerald green jadeite and diamond necklace, ring, and earrings, showcasing a regal and graceful designThe phoenix features in traditional Chinese wedding jewellery, symbolizes auspiciousness and good fortune. Exhibitor Lao Feng Xiang Jewellery Hong Kong Limited presented a "China chic" wedding collection imbued with Oriental charm, crafting accessories that embody the imperial elegance of a royal court for womenWebsites Hong Kong International Jewellery ShowExhibition websitehttp://hkjewelleryshow.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcecActivity listhttps://www.hktdc.com/event/hkjewellery/tc/intelligence-hub Hong Kong International Diamond, Gem & Pearl ShowExhibition websitehttp://hkdgp.hktdc.com/tcShuttle bus detailshttps://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-aweActivity listhttps://www.hktdc.com/event/hkdgp/tc/intelligence-hubHKTDC Media Room: https://mediaroom.hktdc.com/enMedia enquiriesPlease contact HKTDC’s Communication & Public Affairs Department:Winnie KanTel: (852) 2584 4055Email: winnie.wy.kan@hktdc.orgKaty WongTel: (852) 2584 4524Email: katy.ky.wong@hktdc.orgJane CheungTel: (852) 2584 4137Email: jane.mh.cheung@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Chinese Mainland, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 由香港贸易发展局（香港贸发局）主办的全球最大一站式珠宝商贸平台，将于3月初以「两展两地」的成功模式揭幕。第12届香港国际钻石、宝石及珍珠展于3月2至6日在亚洲国际博览馆举行，展出各类珠宝原材料。第42届香港国际珠宝展则于3月4至8日假湾仔香港会议展览中心举办，展示各款珠宝首饰成品。香港贸发局副总裁古静敏表示：「今届珠宝双展将云集逾40个国家及地区、约4,000家展商，当中七成来自香港以外的地区，其中巴西、阿联酋和印度展商更扩大参展规模，而乌兹别克更是首次参展。香港贸发局积极打造全球最大一站式珠宝商贸平台，凸显香港作为国际商贸及珠宝採购中心的地位。」回顾环球珠宝市场，2025年本港贵重珠宝出口至东盟录得51%升幅，而出口至英国、澳洲及瑞士的增长分别按年上升36%、28%及10%。两展云集逾40个展团 硬足金展馆开启金饰新篇章珠宝双展一直备受环球业界支持，今年云集超过40个展团，当中包括中国内地、台湾、印度、以色列、韩国、缅甸、新加坡、斯里兰卡、泰国、乌兹别克、比利时、德国、意大利、西班牙、土耳其、巴西、哥伦比亚、墨西哥及美国等。世界黄金协会将首设硬足金展馆，合共11家中国内地展商，向国际市场展示崭新黄金技艺，目标以展会作「出海」平台，开拓环球商机。此外，今年香港表厂商会首次组团参展，来自湖北的竹山绿松石展团也首度亮相。而坦桑石协会、彩色宝石协会、亚太区创作师协会及亚洲珠宝文化设计工艺协会亦将继续参展，香港珠宝玉石厂商会将联同Italian Exhibition Group（IEG）再度设馆，展示制造珠宝的最新设备和技术。国际品牌 瞩目登场香港国际珠宝展的「品牌精粹廊」展区（Hall of Fame）载誉归来，规模较去年增加逾四成，匯聚更多国际知名珠宝品牌；其中土耳其领先钻石珠宝品牌 Zen Diamond（展位：CEC 3B-C12）将带来採用精细裁切工艺的钻戒系列。于「珠宝精粹廊」展区（Hall of Extraordinary），香港展商恒和钻石（展位：CEC GH-C07）则展出一枚18K白金及玫瑰金镶嵌蓝钻与浅彩粉钻戒指。 另一香港展商Unique Brilliant Limited（展位：CEC GH-C13）将展示一套项链与耳环组合，红宝石未经加热处理，呈现珍稀的「鸽血红」（pigeon blood red）色泽。东方美学展现非遗工艺今年展会云集多款承载东方文化的珠宝。来自中国内地的广东嘉宝阁传世珠宝（展位：CEC GH-A16），带来以国家级非遗工艺「花丝镶金」，以人手制作的蝴蝶胸针，耗时逾四个月。另一内地展商赛菲尔珠宝（展位：CEC 3E-E02）则带来了「宫廷新中式」风格的作品，运用六项古法黄金工艺制作而成，将传统技艺展现在当代首饰上。内地近年兴起硬足金技术，高纯度和高硬度的特性，令金饰可以融入更多时尚和现代设计元素。由世界黄金协会举办的研讨会将分析最新的黄金市场情况和硬足金技术。展会期间将举行多场关于东方美学珠宝的活动。香港珠宝首饰业商会主办的香港国际时尚足金饰设计比赛，鼓励设计师创作出迎合东盟及中东年轻市场，兼具文化内涵和商业潜力的金饰作品，颁奖典礼将于展会期间举行。由香港玉器商会主办，首届国际翡翠玉器首饰设计大赛2026亦会在展会期间举行颁奖典礼。创意设计领潮流紧贴潮流及具创意的产品有助业界突围而出。有展商将创新构思化成潮流产品，Austy Lee Company Limited（展位：CEC 1E-F32）趁马年将至，推出以斑马纹理为设计灵感的手镯。今年「珠宝设计精选」展区（Designer Galleria）迎来新展商Zheng Hong Collective（展位：CEC 1CON-067A），带来一款飞鱼胸针，佩戴时翅膀和尾端会随身体而摆动。今年香港珠宝设计比赛以「未琢之韵．自然之美」为题，启发本地学生及业界精英以作品演绎大自然之美与设计故事，凸显珠宝设计的多元面貌，大会将于展会期间公佈赛果。稀世瑰宝闪耀双展两展一直为买家网罗古典珍藏及稀有珠宝，香港国际珠宝展的香港展商拾玑古董珠宝（展位：CEC CH-F13）展出20 世纪、70 年代制作的布契拉提粉色蓝宝石套装。另有展商 World Coins Co., Ltd. （展位：CEC CH-N12）带来19世纪意大利工匠的双色珐琅钻石首饰，首饰连同原盒完整保存至今超过100年。香港国际钻石、宝石及珍珠展则有德国展商Caram e.K. （展位：AWE 8-F05）带来18.98卡AGL认证、收藏级的天然粉红蓝宝石；加大拿展商Korite Ammolite Ltd（展位：AWE 8-F35）展示18K金AA级斑彩石配钻石颈鍊。活动方面，香港国际珠宝展将举行「珠宝风格从何而来？探究时代与工艺的印记」座谈会，特别邀请英国着名歷史学家及珠宝权威 Dr. Jack Ogden主讲，深入剖析珠宝工艺演进及时代审美变迁。逾20场论坛活动 探讨AI及网络营销等业界热话珠宝双展期间将举行超过20 场行业讲座与交流活动，涵盖行业趋势、网络营销和珠宝科技等，其中香港国际珠宝展第二日将剖析人工智能如何由设计走到商业化，推动珠宝行业发展。另外大会将安排研讨会，网红分享如何利用电商平台提高珠宝品牌的影响力、增加销售和实践经验等，让业界加快打通线上线下的协同合作渠道。体验与服务并重 全球买家首选平台展览吸引环球大型珠宝零售连锁店、高端、轻奢及设计师珠宝品牌到场採购，为买卖双方缔造商机，并推动业界交流。此外，香港贸发局为持续优化世界各地买家来港採购的体验，联同香港旅游发展局及多家企业推出买家专属优惠，涵盖餐饮、机票、酒店等，让参观珠宝双展的买家，同时感受香港独有魅力。大会将安排免费穿梭巴士，接载买家往返亚洲国际博览馆及市区（包括湾仔香港会议展览中心），详情请参阅展会网站。线上线下相结合 便利入场洽商採购今年珠宝双展将沿用「展览+」（EXHIBITION+）线上线下融合模式，除了在展会现场採购，由2月23日至3月13日，「商对易」(Click2Match）的人工智能会为展商及买家提供线上商贸配对。在场买家则可利用「扫码易」（Scan2Match）扫描展商的二维码，于展会期间或之后随时随地于线上洽谈。在买家入场方面，「香港贸发局商贸平台」流动应用程式（HKTDC Marketplace App）及两展的官方网页都提供网上验证功能。买家只需透过上述平台登记、上传照片和有效证件，即可获取已验证的买家证，无需现场排队登记或验证，大大提升採购效率。图片下载︰https://bit.ly/4ayrcAo香港贸发局副总裁古静敏（中）、香港贸发局珠宝业谘询委员会主席周允成（左）以及香港贸发局香港国际珠宝展及香港贸发局香港国际钻石、宝石及珍珠展筹备委员会主席黄绍基（右），出席今天（2月5日）举行的香港国际珠宝展和香港国际钻石、宝石及珍珠展新闻发佈会。古静敏（前排左三）连同一众香港贸发局香港国际珠宝展及香港国际钻石、宝石及珍珠展筹备委员会委员，以及表演嘉宾合照。艺人陈晓华（右三）率领一众模特儿演绎各款瑰丽珠宝。艺人陈晓华佩戴展商安东公司带来的天然缅甸翡翠套装，碧绿晶莹的翡翠钻石颈链、戒指及耳环，设计高贵优雅。凤凰常见于中式婚嫁饰品，象徵吉祥、如意，展商老凤祥带来富有中式魅力的国潮婚嫁系列，打造女性宫廷般尊贵的饰品。相关网页 香港国际珠宝展展览网页http://hkjewelleryshow.hktdc.com/tc两展穿梭巴士安排https://www.hktdc.com/event/hkjewellery/tc/travel-to-fairground-hkcec展会活动https://www.hktdc.com/event/hkjewellery/tc/intelligence-hub 香港国际钻石、宝石及珍珠展展览网页http://hkdgp.hktdc.com/tc两展穿梭巴士安排https://www.hktdc.com/event/hkdgp/tc/travel-to-fairground-awe展会活动https://www.hktdc.com/event/hkdgp/tc/intelligence-hub香港贸发局新闻中心：http://mediaroom.hktdc.com/tc传媒查询香港贸易发展局传讯及公共事务部：简惠宜电话：(852) 2584 4055电邮：winnie.wy.kan@hktdc.org黄家欣电话：(852) 2584 4524电邮：katy.ky.wong@hktdc.org张敏萱电话：(852) 2584 4137电邮：jane.mh.cheung@hktdc.org香港贸易发展局简介香港贸易发展局(香港贸发局)是于1966年成立的法定机构，负责促进、协助和发展香港贸易。香港贸发局在世界各地设有超过50个办事处，其中13个设于中国内地，致力推广本港作为双向环球投资及商业枢纽。 香港贸发局通过举办国际展览会、会议及商贸考察团，为企业(尤其是中小企)开拓内地和环球市场的机遇。香港贸发局亦通过研究报告和数码资讯平台，提供最新的市场分析和产品资讯。有关香港贸发局的其他资讯，请浏览www.hktdc.com/aboutus/tc。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – Banle Group (“Banle” or the “Group”), a leading Asia-Pacific marine fuel logistics provider, hosted its landmark inaugural ESG Forum — "Charting the New Horizon: Powering Green Shipping with Sustainable Fuels" — uniting top maritime executives, financiers, legal experts, and climate scientists to address the shipping industry's urgent decarbonization challenges on February 2.Speaker Lineup Tackles Critical IssuesThe forum featured exclusive insights from:Dr. Teck Lim Chia, Chairman and CEO of Banle GroupMs. Karen Cheah Yee-Lynn, Independent Director of Banle Group, Partner of Chooi & Company, Immediate Past President of the Malaysian Bar and EXCO Member of LAWASIAMr.Matt Liu Ming-Hsuan, SVP Capital Solutions, Cathay United BankDr.Wilson Cheung Wai-yin, Polar Explorer, Glaciologist and Policy Advisor, Polar Research and Expedition ConsultancyMs.Rebecca Zhang, Senior Manager Sustainable Finance, Commercial Banking, Hong Kong, HSBCThe forum served as a dynamic platform for thought leadership and dialogue, featuring a series of presentations addressing critical topics such as the impact of climate change on global shipping, evolving sustainability-related regulations, and innovative green and sustainability-linked financing solutions.Dr.Teck Lim Chia addressed in the keynote speech, “The global shipping industry stands at a pivotal moment. Rapid regulatory changes, geopolitical tensions, climate challenges, and technological advancements are reshaping the landscape at unprecedented speed. Yet, we are dedicated to fostering a collaborative environment where stakeholders can come together to share insights and develop strategies for a more sustainable future.”On the forum, Ms.Karen Cheah talked about how ESG has become a legal, economic, and moral imperative to safeguard planetary health – and how governments, businesses, courts, and capital markets at an international level must work together holistically to turn sustainability from aspiration into measurable action. She said, “We must establish planetary health metrics to track environmental, health, and risk impacts on all of us. This requires not only a measurement to gauge our progress but also a strategic plan to communicate these metrics, drive global awareness, and educate society at large. Moreover, we must integrate these metrics into governance structures at organizational, domestic, national, and international levels. We must engage in responsible business practices aligned with ESG components and ensure a robust framework for planetary health is implemented globally. Once we align collectively, we can systemize this framework for lasting impact.”Mr.Matt Liu shared his insight on integrating ESG features into financing strategies, “Green loans excel when companies have a clear, specific investment plan. Sustainability-Linked Loans (SLLs) operate under a distinct logic: their Key Performance Indicators (KPIs) must reflect material sustainability issues, be measurable, traceable, and independently verifiable. Crucially, Sustainability Performance Targets (SPTs) must balance ambition with feasibility, remaining achievable within the company’s operational capacity. Unlike green loans, SLLs do not restrict proceeds to green activities; instead, they demonstrate sustainability commitment through performance-linked financial mechanisms. Beyond loans and bonds, nearly all liability-style financial products can now integrate green or sustainability elements. This flexibility allows companies to align financing with sustainability goals while maintaining operational practicality, driving both environmental progress and financial innovation.”Dr.Wilson Cheung addressed his dedication to geoscientific education and advocacy, and talked about the responsible opportunities for the shipping industry, “Responsible opportunities in the shipping industry begin with recognising that the Arctic is not only a shortcut, but also a living homeland and a fragile climate regulator for the planet. New polar sea routes can reduce transit time and fuel use, yet they cross waters where infrastructure is scarce, ecosystems are vulnerable, and Indigenous communities depend on sea ice for culture and survival. True leadership means investing in cleaner fuels, ice-class vessels, and robust search-and-rescue capacity, while strictly limiting black carbon emissions and respecting international polar regulations. It also means listening to local knowledge that has guided safe travel on ice for thousands of years and integrating that wisdom with modern science and satellite data. If the industry embeds ESG principles into every Arctic voyage, these emerging routes can become a model of responsible innovation rather than a new frontier of unchecked risk.”Ms.Rebecca Zhang shared recent shipping industry transition trends from a sustainable finance perspective: “Regulations are constantly evolving, and so must global efforts to tackle climate change and make maritime transport more sustainable. Innovative solutions are emerging, and shipowners are exploring alternative energy options such as biofuels, bio-LNG, and bio-gas. The development of clean technologies is accelerating the industry’s systemic shift towards sustainability.”The forum concluded with a lively and interactive networking among participants, who exchanged ideas and reaffirmed their collective commitment to advancing sustainable practices throughout the shipping industry.Banle Group's sustainability leadership by example through its operational practices was prominently showcased, highlighting its ongoing efforts to spearhead industry decarbonization and responsible practices. Through initiatives like its participation in the EcoVadis rating system and advocacy for diverse sustainable marine fuels, Banle continues to drive meaningful transformation across the shipping sector.Looking ahead, the Banle Group remains committed to hosting future forums that foster dialogue, innovation, and collaboration for a more sustainable maritime ecosystem.Dr.Teck Lim Chia added: "This is just the beginning. Banle will continue driving practical decarbonization solutions for our industry and clients."For more information about Banle Group and its sustainability initiatives, please visit www.banle-intl.com.Photo Caption 1: Dr. Teck Lim Chia (centre) presented souvenirs to all speakers and panelists as a token of appreciation.Photo Caption 2: Panelists engaged in a discussion on the theme: “Charting the New Horizon: Powering Green Shipping with Sustainable Fuels”. Ms. Karen Cheah (left) served as moderator, guiding the discussion while also contributing her insights as a panelist.Photo caption 3: Attendees gathered at the ESG Forum, showcasing a shared commitment to sustainable practices and innovative solutions in the shipping industry.About Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications, as well as EcoVadis Silver Medal.For more information, please visit: https://www.banle-intl.com. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 亚太地区燃油供应服务商万利集团（以下简称（「万利」或（「集团」）于2月2日举办以「开拓新视野：以可持续燃料推动绿色航运」为主题的首届环境、社会与治理（ESG）论坛。论坛汇聚航运高管、金融家、法律专家及冰川学家，共同探讨应对航运业迫切减碳挑战的方案。以下演讲嘉宾阵容于论坛探讨关键议题，分享独特见解：万利集团主席兼行政总裁谢威廉博士万利集团独立董事、Chooi & Company合伙人、马来西亚大律师公会前会长及LAWASIA执行委员会委员谢依玲女士国泰世华银行资本市场暨顾问部协理刘名轩先生极地探险家、冰川学家及政策顾问、Polar Research and Expedition Consultancy创办人／冰川学家与远征总监张伟贤博士汇丰香港工商金融可持续金融高级经理张雯瑾女士是次论坛为思想领袖提供了一个互动及对话的平台，并透过演讲嘉宾的专题讲座探讨若干关键议题，包括气候变化对全球航运的影响、持续转变的可持续发展相关法规，及创新绿色及可持续发展挂钩融资解决方案。谢威廉博士在主题演讲中表示：「全球航运业正处于关键时刻，迅速转变的监管法规、紧张的地缘政治局势、气候挑战及技术发展正以前所未有的速度重塑行业格局。因此，我们期望打造一个协作环境，让持份者聚首一堂，分享见解并制定策略，以构建可持续未来。」在论坛上，谢依玲女士讨论ESG如何成为保障地球健康的法律、经济和道德必要条件，并强调政府、企业、法院及资本市场必须在全球层面上通力合作，将可持续发展愿景转化为可量化的实际行动。谢女士表示：「我们必须建立全球健康指标体系，以系统追踪环境影响、健康影响及风险对全人类的综合作用。这不仅需要量化工具评估进展，更需制定战略传播方案以提升全球认知、推动全民教育。同时，必须将指标体系深度融入组织、国家及国际治理架构，在本土和全球层面同步实施。企业应践行负责任的商业伦理，全面对标ESG准则，构建普适性的全球健康框架。唯有通过全球协同标准化，方能实现框架的系统化落地与长效运行。」刘名轩先生分享其对将ESG特征融入融资策略的见解：「绿色贷款（Green Loans）在企业拥有明确、具体的投资计划时尤其适合。可持续发展挂钩贷款（Sustainability-Linked Loans，SLLs）遵循独特的逻辑：其关键绩效指标（KPIs）必须反映重大的可持续议题，并且可量化、追踪和独立验证。最重要的是，可持续性绩效目标（Sustainability Performance Targets，SPTs）必须在『积极进取』和『实际可行』之间取得平衡，确保在公司的运营能力范围内有机会实现目标。与绿色贷款不同，SLLs不限制所得款项只用于绿色活动上；相反，SLLs通过与绩效挂钩的金融机制展示可持续承诺。除了贷款和债券，几乎所有负债型金融产品现在都可以加入绿色或可持续性元素。这种灵活性使得企业能够将融资与可持续目标结合在一起，一方面保持运营的实际可行性，也能推动环境进步与金融创新。」张伟贤博士分享其对地球科学教育与倡导的坚定承诺，并探讨航运业的负责任发展机遇：「航运行业的可持续发展机遇始于认识到北极不仅是一条捷径，更是一个生机勃勃的家园和地球脆弱的气候调节器。新开通的极地航线虽能缩短运输时间、降低燃油消耗，但其航经水域存在基础设施匮乏、生态系统脆弱、原住民依赖海冰维系文化与生存等挑战。真正的领导力意味着要投资于更清洁的燃料、冰级船舶和强化搜救能力，同时严格限制黑碳排放（Black Carbon Reduction），并尊重国际极地法规。这也意味着倾听在冰上安全旅行了数千年的地方知识，并将这种智慧与现代科学和卫星数据融合。如果行业将ESG原则嵌入到每一次北极航行中，这些新兴航线能够成为可持续创新的典范，而非不受控制风险的新边界。」张雯瑾女士从可持续金融角度分享航运业转型趋势：「监管不断变化，应对气候目标和实现可持续海洋运输的策略亦需要与时并进。目前，创新方案也应运而生，船东群体正探索生物燃料、生物液化天然气（bio-LNG）、生物沼气等替代能源方案。清洁技术研发持续，有助推动全球航运业向可持续模式的系统性转型。」论坛在与会人士热烈交流中圆满结束，除交流意见外，他们亦重申对推动航运业可持续发展的共同承诺。万利集团在可持续发展领域的领导地位突出，显示其在引领行业减碳与推行负责任实践方面的不懈努力。集团亦透过参与EcoVadis永续性评级系统及支持多元化可持续船用燃料，持续推进航运业的有效转型。展望未来，集团将继续举办更多论坛，促进对话交流、创新及合作，从而建立更可持续的海洋生态系统。谢威廉博士补充：「以上不过是个开端，万利将继续为行业及客户制定切实可行的减碳解决方案。」有关万利集团及其可持续发展方案的更多讯息，请浏览 www.banle-intl.com。图片说明1：谢威廉博士（中）向演讲嘉宾及论坛成员致送纪念品以示感谢。图片说明2：论坛成员就「开拓新视野：以可持续燃料推动绿色航运」主题进行讨论。谢依玲女士（左）担任主持人，引领讨论并以论坛成员身份分享见解。图片说明3 ：与会人士在 ESG 论坛上聚集，展现了对航运业可持续实践和创新解决方案的共同承诺。关于万利集团万利集团成立于 2015 年，以CBL International Limited（纳斯达克：BANL）在纳斯达克股票市场上市。我们致力于为客户提供一站式燃油供应服务，被业内称为燃油供应服务商。我们主要通过当地实体供货商为船舶提供燃油加注服务，遍布比利时、中国、香港、印度、日本、韩国、马来西亚、毛里裘斯、巴拿马、菲律宾、新加坡、台湾、泰国、土耳其和越南，共覆盖65个港口。集团积极推动可持续燃料，并已取得ISCC EU和ISCC Plus认证，以及EcoVadis银奖。如欲了解更多信息，请到集团网站 https://www.banle-intl.com 浏览。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRISBANE, AUS, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - Annature, Australia's leading eSignature and Identity verification provider, has announced the release of its 21 CFR Part 11 compliant electronic signature module, enabling organisations operating in FDA‑regulated environments to execute electronic records with confidence.The new capability ensures Annature customers can meet the U.S. Food and Drug Administration's requirements for electronic records and electronic signatures under 21 CFR Part 11, a regulation that governs data integrity, signer authentication, and auditability across industries such as life sciences, pharmaceuticals, biotechnology, and clinical research.The release has been driven by growing demand from U.S.-based and multinational organisations seeking a modern, compliant alternative to legacy eSignature platforms. Several customers operating in regulated environments have already transitioned to Annature as part of broader digital transformation initiatives, prompting the company to formally introduce Part 11 support as part of its international product roadmap."As we continue to grow globally, it's critical that Annature supports the regulatory frameworks our customers operate under," said Corey Cacic, CEO of Annature. "Our 21 CFR Part 11 module allows organisations subject to FDA requirements to use Annature with confidence, knowing their electronic signatures meet the necessary compliance standards."The module introduces controls aligned with Part 11 expectations, including secure signer authentication, tamper‑evident audit trails, and strong linkage between electronic signatures and the records they relate to. These features ensure electronic signatures executed through Annature can be relied upon in regulated workflows and during regulatory review.Kim Steel, Founder and Managing Director of SAPRO - a boutique CRO supporting niche biotech and pharmaceutical companies with commercially sponsored Phase I-III full-service clinical trials has welcomed the release."For organisations operating in regulated environments, compliance with 21 CFR Part 11 is not optional - it is fundamental," said Steel. "It is encouraging to see Annature, an Australian technology provider supporting international regulatory requirements that are critical to our industry and our clients. Solutions like this enable sponsors to operate confidently on a global stage, without reliance on outdated or overly complex legacy systems, while remaining inspection and audit-ready at all times."The launch further strengthens Annature's position as a global‑ready eSignature platform, supporting organisations that operate across jurisdictions with varying compliance obligations. The 21 CFR Part 11 module is available now and can be enabled for customers who require FDA‑compliant electronic signatures.About AnnatureAnnature is Australia's leading eSignature and Identity verification provider, trusted by over 6,700 businesses. With a Pay as you go model and deep integration across the business app ecosystem, Annature delivers secure, affordable, and locally supported solutions for professionals across the country. Annature's growing product suite also includes integrated payments and compliance features designed to support both domestic and international regulatory requirements.https://www.annature.com.auCONTACT:Name: Corey CacicEmail: corey@annature.com.auSOURCE: Annature Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

MORTSEL, BE, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) - AGFA HealthCare today announced that it has been named Best in KLAS® 2026 across three Enterprise Imaging segments in the United States, with two awards earned for the second consecutive year, underscoring the company's continued leadership in delivering clinician-first imaging solutions trusted by healthcare organizations worldwide.The recognition comes as KLAS Research marks its 30th anniversary, celebrating three decades of amplifying the voice of healthcare providers through independent, data-driven insights.AGFA HealthCare's Best in KLAS distinctions reflect strong customer validation of its Enterprise Imaging platform - designed to empower clinicians to stay in their flow, reduce complexity across imaging workflows, and enable confident clinical decision-making through connected, high-performing access to images and data.Best in KLAS® - Enterprise Imaging (United States)Enterprise Imaging for Radiology: ranked #1 with a 93.2% score in the PACS (Small - under 300k studies) segment.XERO® Viewer: ranked #1 with a 92.1% score in the Universal Viewer (Imaging) segment for the third consecutive yearEnterprise Imaging VNA: ranked #1 with a 89.8% score in the Vendor Neutral Archive (VNA) segment for the second consecutive year."Being recognized across three Enterprise Imaging segments - including multiple consecutive wins - is a powerful affirmation of our clinician-first strategy," said Nathalie McCaughley, President of AGFA HealthCare. "Healthcare organizations trust us to deliver imaging environments that truly support clinicians in their daily work, while enabling IT and clinical leaders to operate with confidence, performance, and long-term vision. This recognition reflects the strength of our partnerships and our unwavering focus on empowering care teams through connected, intelligent imaging."Commenting on the awards, Adam Gale, CEO of KLAS Research, said:"The Best in KLAS winners have earned the trust of their customers over the past year. With this recognition, they set the standard for excellence through partnership in healthcare technology and services in the months to come."Monique Rasband, Global Vice President of Imaging at KLAS Research, added:"AGFA HealthCare's strong performance across multiple Enterprise Imaging segments reflects consistent customer feedback. Organizations recognize the value of solutions that help imaging teams work efficiently today while providing a clear path for future growth and innovation."The Best in KLAS awards are based on direct feedback from healthcare providers and recognize vendors who consistently demonstrate excellence through partnership, performance, and responsiveness to customer needs.AGFA HealthCare will celebrate its Best in KLAS recognition during HIMSS 2026, alongside customers and partners, as part of its continued commitment to advancing connected, intelligent, and human-centered imaging at scale.KLAS referencesBest in KLAS Awards overview: 2026 Best in KLAS Awards: Software and Services ReportEnterprise Imaging segments reports: 2026 Best in KLAS Awards: Software and Services ReportAbout AGFA HealthCareAt AGFA HealthCare, we understand that striking the critical balance between clinical efficiency and quality patient care starts with the clinician experience. We recognize how vital it is for clinicians to be fully immersed in their cases, channeling all their energy into delivering confident, informed diagnoses. That's why we designed our Enterprise Imaging platform to eliminate the barriers that get in the way. When distractions melt away, technology feels like an extension of one's thought process, and each clinician has everything they need to perform at the top of their craft. That's life in flow.This belief shapes everything we do - guided by our Mission, Vision, and Customer Delivery Principles, which are designed to empower clinicians and elevate their experience.AGFA HealthCare is a division of the Agfa-Gevaert Group. For more information on AGFA HealthCare, please visit www.agfahealthcare.comand follow us on LinkedIn.AGFA and the Agfa rhombus are registered trademarks of Agfa-Gevaert N.V. Belgium or its affiliates. XERO is a registered trademark of Agfa HealthCare N.V. Belgium or its affiliates. All information contained herein is intended for guidance purposes only, and the characteristics of the products and services described in this publication can be changed at any time without notice. Products and services may not be available for your local area. Please contact your local sales representative for availability information. AGFA HealthCare diligently strives to provide as accurate information as possible but shall not be responsible for any typographical error.About KLAS ResearchKLAS Research is a leading healthcare IT data and insights company dedicated to improving global healthcare delivery by amplifying the voice of healthcare providers. Celebrating its 30th anniversary in 2026, KLAS evaluates vendor performance through independent research based on direct customer feedback.Best in KLAS® is a registered trademark of KLAS Research.Press Contact: Jessica Baldry, Global Marketing & Communications Manager, AGFA HealthCare +44 1206 413052 jessica.baldry@agfa.comSOURCE: Agfa HealthCare Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

OSAKA, Japan, Feb 5, 2026 - (ACN Newswire via SeaPRwire.com) – February 4, 2026, SuperX Industries Co., Ltd. ("SuperX"), a Japanese subsidiary of SuperX AI Technology Limited (“NASDAQ:SUPX”), today announced the signing of an Memorandum of Understanding ("MOU") on February 4, 2026 with Digital Dynamic Inc. ("DD"), eole Inc. ("eole"), and Woodman Inc. ("Woodman"). This MOU builds on the parties’ prior cooperation to establish a comprehensive framework for the co-development of large-scale AI Data Centers (AIDC) across Japan.Advancing the Mie Prefecture Pilot ProjectFollowing the first MOU signed on January 30, 2026 in Osaka, Japan, the Parties entered into the MOU to further deepen collaboration by establishing a joint task force to pilot an AIDC project in Mie Prefecture, Japan with an initial facility capacity up to 4MW, subject to feasibility assessments, site conditions, regulatory approvals, and the execution of definitive agreements. The pilot initiative is intended to serve as a starting point for assessing potential future expansion up to 300MW in total capacity.Addressing Japan’s AI Infrastructure BottleneckThe shift toward modular architecture directly addresses Japan’s growing demand for the expansion of domestic AI capacity on an accelerated timeline. Unlike traditional "brick-and-mortar" builds that can take years to complete, SuperX’s modular approach accelerates deployment by reducing construction timelines significantly. This new pilot project is designed to be purpose-built for next-generation, liquid-cooled GPUs—capabilities often lacking in legacy data centers.Scalable delivery and reliable operationsPursuant to the MOU, the Parties intend to collaborate on the system-level integration of critical infrastructure, including advanced power systems and liquid cooling solutions essential for continuous AI workloads. The framework also contemplates the future integration of renewable energy components, such as solar and wind power, energy storage systems, and grid interconnection, subject to site conditions, commercial viability and regulatory approvals.To facilitate execution, a joint task force is expected to be established to define technical architecture, governance, and near-term milestones. SuperX will lead the provision of the modular system architecture and power system integration.Executive quote“Speed-to-market is the new currency in the AI race,” said Aiko Furukawa, the CEO of SuperX Industries Co. Limited. “This pilot project in Mie Prefecture is intended to demonstrate how we can deploy AI infrastructure with speed. Alongside our partners, we aim to demonstrate that modular scalability is the most viable path to meeting Japan's surging demand for AI.”Looking aheadLooking forward, the Parties intend to use the initial pilot as a reference framework to evaluate broader modular AIDC opportunities across Japan, including scalable pathways for expansion—subject to further feasibility assessments, regulatory approvals, site conditions, and the negotiation and execution of definitive agreements.About Digital Dynamic IncDigital Dynamic Inc. is one of Japan’s fastest-growing AI infrastructure operators, with a rapidly expanding deployment of NVIDIA-based inference GPU resources. In 2026, the company plans to complete AI data centers in Kagoshima Prefecture and Fukushima Prefecture, reinforcing Japan’s next-generation AI computing foundation.About eole Inceole Inc. is a publicly listed company in Japan with a rapidly growing presence in the domestic GPU server market. The company provides investment and business development support for AI data center development projects, playing an active role in advancing Japan’s AI infrastructure ecosystem.About Woodman IncWOODMAN Inc. is a Japanese technology company focusing on eliminating societal waste by transforming underutilized resources, such as surplus electricity and computing power, into new value. They specialize in constructing optimized computing environments for AI and HPC (High-Performance Computing), bridging the gap between energy infrastructure and, previously, blockchain/mining hardware.About SuperX AI Technology Limited (NASDAQ:SUPX)SuperX AI Technology Limited is an AI infrastructure solutions provider, offering a comprehensive portfolio of proprietary hardware, advanced software, and end-to-end services for AI data centers. The Company's services include advanced solution design and planning, cost-effective infrastructure product integration, and end-to-end operations and maintenance. Its core products include high-performance AI servers, 800 Volts Direct Current (800VDC) solutions, high-density liquid cooling solutions, as well as AI cloud and AI agents. Headquartered in Singapore, the Company serves institutional clients globally, including enterprises, research institutions, and cloud and edge computing deployments. For more information, please visit www.superx.sgSafe Harbor Statement This press release may contain forward-looking statements. In addition, from time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. You can identify forward-looking statements by those that are not historical in nature, particularly those that use terminology such as "may," "should," "expects," "anticipates," "contemplates," "estimates," "believes," "plans," "projected," "predicts," "potential," or "hopes" or the negative of these or similar terms. In evaluating these forward-looking statements, you should consider various factors, including: our ability to change the direction of the Company; our ability to keep pace with new technology and changing market needs; and the competitive environment of our business. These and other factors may cause our actual results to differ materially from any forward-looking statement.Forward-looking statements are only predictions. The reader is cautioned not to rely on these forward-looking statements. The forward-looking events discussed in this press release and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties, and assumptions about us. We are not obligated to publicly update or revise any forward-looking statement, whether as a result of uncertainties and assumptions, the forward-looking events discussed in this press release and other statements made from time to time by us or our representatives might not occur. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

上海, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 云顶新耀（HKEX 1952.HK，以下简称"公司"），一家专注于创新药研发、临床开发、制造及商业化的生物制药公司，今日宣布与陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）签署独家商业化许可协议，获得MT1013在中国及亚太区（日本除外）的独家商业化授权。MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体(CaSR)及成骨生长肽(OGP)受体，开发主要用于治疗继发性甲状旁腺功能亢进症(SHPT)。此次战略合作将与云顶新耀现有肾科管线形成协同效应，强化产品布局，巩固公司在亚洲肾脏及自身免疫疾病领域的领导地位，并将产品覆盖从IgA肾病拓展至更广泛的慢性肾脏病领域。根据协议，云顶新耀将向麦科奥特支付人民币2亿元首付款，以及最高不超过人民币10.40亿元的潜在监管及商业里程碑付款。中国III期临床研究正在进行中，相关临床开发费用将由麦科奥特承担。MT1013是由麦科奥特自主研发的全球首创双靶点多肽新药，2025年获美国肾脏病学会（ASN）年会"Late-Breaking"收录。其开创性地融合了"钙敏感受体（CaSR）+成骨生长肽（OGP）模拟"双重作用机制，解决了PTH、钙、磷代谢平衡的问题，这一全新设计使其在治疗继发性甲状旁腺功能亢进（SHPT）及相关骨代谢疾病时，首次创造性的从源头上控制病情，且能通过直接激活成骨通路，主动促进骨形成与修复，实现从"间接抑制骨吸收"到"主动促进骨生成"的治疗创新升级。临床研究证实，MT1013在慢性肾病接受维持性血液透析伴继发性甲状旁腺功能亢进患者中，起效迅速、效力强且持久，安全性良好，在综合达标率（iPTH, 血钙，血磷均达标）、血钙钙化指标的控制及心血管获益前景上均展示出超越现有疗法的潜力。目前，MT1013正在中国开展针对该患者群体的III期临床研究，已入组超50%。SHPT是慢性肾脏病（CKD）患者最常见的严重并发症之一。该疾病导致钙磷代谢紊乱、甲状旁腺激素升高、骨病变、血管钙化等一系列病理变化，显著增加骨折、心血管事件和死亡风险，是影响CKD患者预后的关键因素。随着全球慢性肾脏病患者规模持续扩大，SHPT及其相关治疗需求亦不断增长。数据显示，全球CKD患者人数已由2019年的9.052亿人增至2024年的10.655亿人，预计2030年将超12亿人，2035年将超15亿人；同期全球SHPT患者人数亦持续增长，预计2030年将达约1.899亿人，2035年将达约2.217亿人，临床需求亟待满足。云顶新耀董事会主席吴以芳表示："我们非常高兴能与麦科奥特达成此次合作。在全球慢性肾脏病患者持续增加的背景下，继发性甲状旁腺功能亢进仍存在显著临床未满足需求。MT1013作为具备全球首创双重作用机制的临床后期创新资产，有望为SHPT患者提供全新的治疗选择。作为潜在同类最佳药物，MT1013将与公司现有的肾科产品组合形成高度协同，进一步夯实公司在肾科领域的布局。云顶新耀在持续深耕自身免疫相关肾脏疾病的基础上，正加速拓展至肾小球肾炎以及慢性肾脏病及其并发症等更广泛的治疗领域。此次合作是公司完善创新管线、拓展肾科治疗边界的重要战略举措，标志着肾科战略由聚焦单一疾病领域向系统化和平台化的发展阶段升级。未来，双方将协同推进MT1013的开发与商业化，为更广泛的肾病患者提供创新治疗选择。"麦科奥特创始人、董事长王冰博士表示："我们很高兴与云顶新耀达成此次战略合作。云顶新耀在肾病领域拥有深厚的市场积累和成熟的商业化体系，是推动MT1013惠及中国乃至全球患者的理想合作伙伴。MT1013是公司多肽技术平台的重要成果，代表着公司在慢病创新治疗领域深耕的重要里程碑达成，其独特的双靶点机制有望为SHPT治疗带来突破和更多获益。我们期待与云顶新耀紧密协作，加速该产品的临床开发和上市进程，共同满足广大未满足的临床需求，开启肾病领域治疗的全新篇章。"MT1013已完成关键II期临床研究，数据显示，MT1013在维持性血液透析伴SHPT患者中，展现出强效且持久的iPTH抑制能力，并在与依特卡肽头对头比较中实现了综合管理的优势——其iPTH、血钙、血磷三项同时达标率更高，降磷及降低心血管风险标志物FGF-23的优势更强，加之MT1013在长达52周的治疗中也为患者人群带来了显著的骨密度提升及骨代谢标志物改善，逐步验证了其独特的双重机制在SHPT患者中综合管理及改善骨骼健康方面的潜在临床获益。目前MT1013已进入以西那卡塞为阳性对照的确证性III期临床试验。该III期试验已在全国范围内启动超过100家研究中心，计划招募约424名患者，主要针对慢性肾脏病维持性血液透析伴 SHPT的患者群体。关于MT1013MT1013为全球首创的双靶点受体激动剂多肽，可同时靶向钙敏感受体（CaSR）及成骨生长肽（OGP）受体，开发主要用于治疗继发性甲状旁腺功能亢进症（SHPT），并计划拓展至包括慢性肾病性矿物质和骨代谢异常（CKD-MBD）伴骨质疏松及未接受透析的SHPT在内的额外适应症。MT1013已于2025年5月完成针对SHPT的II期临床研究（MT1013-II-C01），并已进入以西那卡塞为对照的III期临床研究。关于云顶新耀云顶新耀是一家专注于创新药研发、临床开发、制造和商业化的生物制药公司，致力于满足全球市场尚未满足的医疗需求。云顶新耀的管理团队在中国及全球领先制药企业拥有深厚的专长和丰富的经验。公司在浙江嘉善拥有具备商业化规模的全球生产基地，并严格按照国家药品监督管理局（NMPA）和欧洲药品管理局（EMA）的 GMP 要求及世界卫生组织（WHO）PQ 标准建设。公司聚焦自身免疫、眼科、急重症及CKM（心血管、肾脏及代谢）等疾病治疗领域，已打造集全渠道商业化体系与药品全生命周期商业化能力于一体的商业化平台，并以拥有全球权益的自研 mRNA 平台为基础，持续推进mRNA in vivo CAR-T 与 mRNA 肿瘤疫苗等现有管线，同时通过引进及生态孵化潜力平台，拓展研发能力，同时强化全球化布局，加快国际化发展进程。更多信息，请访问公司官网：www.everestmedicines.com。关于麦科奥特陕西麦科奥特医药科技股份有限公司（以下简称"麦科奥特"）于2007年1月在西安成立，现已完成西安、苏州、北京、上海、中国香港、美国布局。公司是一家专注于新药研发的创新型医药科技企业，致力于成为双功能和多功能特异性多肽药物研发的领军性前沿企业，聚焦于心脑血管、代谢类疾病相关领域的新药研发。公司是是双特异性多肽概念的提出者、实施者、验证者和开发者，是多肽类药物研发的优秀平台之一，具有筛选多靶点多肽药物的特殊机制，具备开发First-in-class和Best-in-class品种的平台型研发能力，现已储备多个新药品种，其中进入临床研发的有7个原研创新药管线，包括1个临床三期阶段，3个临床二期阶段，3个临床一期阶段。公司致力于创制新药、挽救生命，满足未被满足的临床需求，用科技创新为人类健康保驾护航。更多信息，请访问公司官网：www.micot.cn。前瞻性声明本新闻稿所发布的信息中可能会包含某些前瞻性表述，乃基于本公司或管理层在做出表述时对公司业务运营情况及财务状况的现有看法、相信、和现有预期，可能会使用"将"、"预期"、"预测"、"期望"、"打算"、"计划"、"相信"、"预估"、"确信"及其他类似词语进行表述。这些前瞻性表述并非对未来业绩的保证，会受到风险、不确定性及其他因素的影响，有些乃超出本公司的控制范围，难以预计。因此，受我们的业务、竞争环境、政治、经济、法律和社会情况的未来变化及发展等各种因素及假设的影响，实际结果可能会与前瞻性表述所含资料有较大差别。本公司及各附属公司、各位董事、管理人员、顾问及代理未曾且概不承担更新该稿件所载前瞻性表述以反映在本新闻稿发布日后最新信息、未来项目或情形的任何义务，除非法律要求。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Shanghai, January 5, 2026 - (ACN Newswire via SeaPRwire.com) – Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive license agreement with Shaanxi Micot Pharmaceutical Technology Co., Ltd. (“Micot”) to commercialize MT1013, the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism (SHPT) as its leading indication, in China and Asia-Pacific (excluding Japan).According to the agreement, Everest Medicines will pay Micot an upfront payment of RMB 200 million and potential regulatory and commercial milestone payments of up to RMB 1,040 million. MT1013 has entered Phase III clinical trial in China and the relevant development expenses will be covered by Micot. The strategic collaboration is expected to complement Everest Medicines’ existing renal pipeline and drive operating synergies, further strengthen the Company’s commercial product portfolio, and solidify its leading position in renal and autoimmune diseases in Asia, which are key therapeutic areas of focus. The collaboration will also expand the Company’s nephrology portfolio from IgA nephropathy to a broader range of chronic kidney diseases (CKD).MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide internally developed by Micot. The Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology (ASN) Annual Meeting. MT1013 uniquely combines the calcium-sensing receptor (CaSR) and the osteogenic growth peptide (OGP) receptor, addressing imbalances in parathyroid hormone (PTH), calcium, and phosphate metabolism. This innovative dual mechanism allows MT1013 to control SHPT and related bone metabolism disorders at the source, and to actively promote bone formation and repair through direct activation of osteogenic pathways, representing a therapeutic innovation shift from indirect inhibition of bone resorption to active stimulation of bone formation.Clinical studies have demonstrated that MT1013 acts rapidly, with strong and durable efficacy, and has a favorable safety profile in patients with CKD on maintenance hemodialysis with SHPT. It has shown potential advantages over current therapies in achieving comprehensive endpoints, including control of intact parathyroid hormone (iPTH), serum calcium, and phosphate levels, as well as improving calcium-phosphate balance and offering potential cardiovascular benefits. MT1013 is currently being evaluated in a Phase III clinical trial in China for this patient population, with over 50% of the target enrollment already achieved. SHPT is one of the most common and serious complications in patients with CKD. It causes disturbances in calcium and phosphate metabolism, elevated PTH levels, bone disorders, and vascular calcification, which substantially increase the risk of fractures, cardiovascular events, and mortality. SHPT is therefore an important factor influencing outcomes and prognosis in patients with CKD. With the global prevalence of CKD continuing to rise, the unmet medical need for effective SHPT therapies is also growing. Data indicate that the global population of patients with CKD has increased from 905.2 million in 2019 to 1.0655 billion in 2024 and is projected to exceed 1.2 billion by 2030 and 1.5 billion by 2035. Over the same period, the number of patients with SHPT has also continued to rise and is expected to reach approximately 189.9 million by 2030 and 221.7 million by 2035, highlighting a substantial and growing unmet medical need.“We are very pleased to collaborate with Micot. As the global burden of chronic kidney disease continues to rise, addressing patients’ unmet needs remains a top priority.,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “MT1013 represents an innovative asset with the potential to expand treatment options for patients with secondary hyperparathyroidism. Through this partnership, we aim to leverage our expertise in autoimmune-related kidney disorders while broadening our renal portfolio to include additional diseases, including glomerulonephritis and complications associated with dialysis. Looking ahead, we will jointly advance the development and commercialization of MT1013 to bring innovative treatment options to a broader population of patients with kidney disease.”“We are delighted to enter into this strategic collaboration with Everest Medicines. Everest’s deep expertise in nephrology and established commercialization capabilities make it an ideal partner to bring MT1013 to patients in China and beyond,” said Dr. Bing Wang, Founder, Chairman, and President of Micot. “MT1013 is a pivotal achievement of our peptide technology platform and a key milestone in our commitment to advancing innovative therapies for chronic diseases. Its unique dual-targeting mechanism has the potential to deliver meaningful advances in the treatment of secondary hyperparathyroidism. We look forward to working closely with Everest to accelerate clinical development and commercialization, address critical unmet medical needs, and advance care for patients with kidney disease.”MT1013 has completed its pivotal Phase II clinical trial, which demonstrated robust and sustained iPTH suppression in patients with SHPT undergoing maintenance hemodialysis. In head-to-head comparisons with etelcalcetide, MT1013 showed advantages in comprehensive disease management, achieving higher rates of simultaneous control of iPTH, serum calcium, and phosphate, as well as greater reductions in phosphate and the cardiovascular risk marker FGF-23. Over 52 weeks of treatment, MT1013 also resulted in significant improvements in bone mineral density and bone metabolism markers, supporting the potential clinical benefits of its unique dual-target mechanism in both disease management and bone health.Building on these positive results, the Phase II data were presented orally and in a Late-Breaking session at the 2025 American Society of Nephrology Annual Meeting. MT1013 has now advanced into a confirmatory Phase III clinical trial in China with cinacalcet as the active comparator. The Phase III study has been launched across more than 100 sites nationwide, aiming to enroll approximately 424 patients, specifically targeting individuals with SHPT undergoing maintenance hemodialysis due to chronic kidney disease.About MT1013MT1013 is the world’s first-in-class dual-targeting receptor agonist polypeptide that simultaneously targets the Calcium-Sensing Receptor (CaSR) and the Osteogenic Growth Peptide (OGP) receptor and is primarily developed with Secondary Hyperparathyroidism as its leading indication and is planned to expand into additional indications including Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) with Osteoporosis and SHPT not on Dialysis. MT1013 completed its Phase II clinical trial (MT1013-II-C01) for the treatment of SHPT in May 2025 and has entered a Phase III clinical trial using Cinacalcet as the active comparator.About Everest MedicinesEverest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.About MicotShaanxi Micot Pharmaceutical TechnologyCo., Ltd.("Micot") was founded in Xi’an in January 2007 and now operates in China (Xi’an, Suzhou, Beijing, Shanghai, Hong Kong) and the U.S. An R&D-driven innovator, Micot develops dual- and multi-functional peptide drugs for cardiovascular/cerebrovascular and metabolic diseases to address unmet clinical needs.As the proposer, implementer, validator, and developer of the bispecific peptide concept, Micot stands as a premier platform for peptide drug R&D. It utilizes a unique mechanism for screening multi-target peptide therapeutics and possesses platform-based R&D capabilities to develop both First-in-class and Best-in-class candidates.Currently, Micot has a robust reserve of new drug candidates, with seven proprietary innovative pipelines currently in clinical stage: one in Phase III, three in Phase II, and three in Phase I. Dedicated to creating breakthrough medicines and saving lives, Micot strives to address unmet clinical needs and leverages scientific innovation to safeguard human health. For more information, please visit the website: www.micot.cn.Forward-Looking StatementsThis news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

东京, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 专注于工业用贵金属展开业务的TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.（总公司：东京都中央区、执行总裁：田中 浩一朗）宣布在以体外诊断试剂为代表的各种检测试剂盒的受托制造业务中，确立了可一站式应对整个工序的全面解决方案体制。TANAKA此前主要开展从检测试剂盒的开发制造到提取液的批量制造的相关业务，此次完善了提取液分装及包装的生产线，实现了在公司内部从开发到最终成品制造完成闭环的一条龙体制。由此不仅降低了外包和运输的相关成本，还缩短了生产周期，使我们能够以更短的期间提供更高质量的产品。此外，我们计划于2026年3月前追加引进最新型的自动装配生产线和提取液分装装置，以进一步扩大产能及缩短备货周期。TANAKA的全面解决方案体制通过强化一条龙生产体制实现灵活应对通过此次确立的全面解决方案体制，我们实现了从检测试剂盒开发制造，到提取液的批量制造及分装、包装等各工序的一站式受托服务。由此不仅能够对客户从开发阶段到量产的过程持续提供支持，还能应对仅药液分装等单一工序的委托。通过生产流程的公司内部闭环，来实现进一步强化稳定供应与质量管理。在广泛的疾病领域中的检测试剂盒的开发实绩与拓展示例我们提供针对流感、新型冠状病毒等呼吸道传染病，以及登革热病毒、寨卡病毒等范围广泛的传染病的体外诊断试剂。这些检测试剂盒可应对唾液、血液、尿液等多种检体，为在医疗领域实现快速精准的诊断提供支持。呼吸道传染病蚊媒传染病妇产科・流感病毒・腺病毒・RS病毒・人偏肺病毒・新型冠状病毒・A群β溶血链球菌（溶连菌）・登革热病毒・寨卡病毒・基孔肯雅热病毒・怀孕检测试剂TANAKA可检测疾病领域拓展示例技术基础与今后的展望TANAKA自2006年左右开始研发体外诊断试剂，不断培养以金（Au）胶体粒子为核心的相关技术。已拥有蛋白质固定化技术、非特异性吸附抑制技术、抗原抗体反应增强技术等，通过免疫层析法实现试剂更高性能化的多种技术。此外，还依托ISO 13485认证，有效利用这些技术，承接更高质量检测试剂盒的委托制造。今后仍将充分利用这一全面解决方案体制，在与合作伙伴企业协作的同时，致力于新型诊断试剂的开发工作，并为解决社会课题和推动医疗领域的发展做出贡献。关于TANAKATANAKA自1885 年（明治18年）创业以来，营业范围以贵金属为中心，并以此展开广泛活动。公司在日本国内拥有非常可观的贵金属交易量, 长年以来不遗余力地进行工业用贵金属制品的制造和销售，以及提供作为宝石饰品及资产的贵金属商品。并且，作为贵金属相关的专家集团，日本国内外的各集团公司进行制造、销售以及技术一体化，携手合作提供产品及服务。2024年度（截至2024年12月)集团总营业额为8,469亿日元，拥有5,591名员工。产业事业全球网站https://www.tanaka.com.cn产品咨询表TANAKA PRECIOUS METAL TECHNOLOGIES Co., Ltd.https://www.tanaka.com.cn/inquiries-on-industrial-products/新闻媒体咨询处TANAKA PRECIOUS METAL GROUP Co., Ltd.https://www.tanaka.com.cn/inquiries-for-media/新闻稿: https://www.acnnewswire.com/docs/files/20260205_CH.pdf Disclaimer:ANY EXPRESS WRITTEN WARRANTY THAT TANAKA MAY ISSUE, IS THE SOLE AND EXCLUSIVE WARRANTY AS TO TANAKA’S MATERIALS AND PRODUCTS, EXTENDS ONLY TO THE INITIAL PURCHASER FROM TANAKA OR ITS AUTHORIZED DISTRIBUTOR, IS NOT TRANSFERABLE OR ASSIGNABLE, AND IS EXPRESSLY IN LIEU OF AND TANAKA EXPRESSLY DISCLAIMS TO THE EXTENT PERMISSIBLE UNDER APPLICABLE LAW ANY OTHER WARRANTY, ORAL OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY ORAL OR IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE.TANAKA SHALL NOT BE LIABLE FOR ANY INCIDENTAL, SPECIAL, OR CONSEQUENTIAL LOSS, DAMAGE, OR EXPENSE (INCLUDING, WITHOUT LIMITATION, LOST PROFITS) DIRECTLY OR INDIRECTLY ARISING FROM THE SALE, INABILITY TO SELL, USE, OR LOSS OF USE OF ANY PRODUCT. NO ORAL OR WRITTEN INFORMATION OR ADVICE GIVEN BY TANAKA, ITS EMPLOYEES, DISTRIBUTORS, DEALERS, OR AGENTS SHALL INCREASE THE SCOPE OF ANY WARRANTY OR CREATE ANY NEW WARRANTIES.THE LIMITATIONS AS STATED HEREIN SHALL NOT PRECLUDE ANY LIABILITY WHICH UNDER APPLICABLE PRODUCTS LIABILITY LAW CANNOT LEGALLY BE PRECLUDED BY CONTRACT OR OTHERWISE.NEVER USE THIS TEST KIT AS THE ONLY GUIDE TO MANAGE YOUR CONDITION OR ILLNESS. CONSULT YOUR HEALTHCARE PROVIDER IF YOUR SYMPTOMS PERSIST OR BECOME MORE SEVERE, OR IF YOU ARE CONCERNED AT ANY TIME. Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

莫尔塞尔，比利时, 2026年2月5日 - (亚太商讯 via SeaPRwire.com) - 阿格法医疗今日宣布，其在美国三大企业影像领域荣获2026年度KLAS®最佳企业称号，其中两项奖项实现连续两年蝉联，彰显了公司在提供以临床医师为核心的影像解决方案方面持续领先的地位，该方案已赢得全球医疗机构的信赖。此次获奖正值KLAS研究公司成立三十周年之际，该机构三十年来始终通过独立、数据驱动的洞察力，为医疗服务提供者发声。阿格法医疗荣获“KLAS最佳”殊荣，充分体现其企业影像平台获得客户高度认可。该平台旨在赋能临床医生保持工作流畅性，简化影像工作流程复杂性，并通过互联高效的影像数据访问能力，助力临床决策信心提升。KLAS®最佳企业影像解决方案（美国）放射学企业影像：在PACS（小型——低于30万份研究）细分领域以93.2%的评分位列榜首。XERO® 影像浏览器：连续三年蝉联通用影像浏览器领域榜首，评分达92.1%企业级影像VNA系统：连续两年稳居供应商中立档案系统（VNA）领域首位，评分达89.8%“在三大企业影像领域获得认可——包括多次蝉联冠军——有力印证了我们以临床医生为核心的战略，”爱克发医疗总裁娜塔莉·麦考利表示，"医疗机构信赖我们打造的影像环境，既能切实支持临床医生的日常工作，又能让IT和临床领导者充满信心地高效运作并具备长远视野。这项荣誉彰显了我们合作伙伴关系的强大力量，以及我们始终如一地致力于通过互联智能影像赋能医疗团队。"KLAS Research首席执行官亚当·盖尔对此评价道：“最佳KLAS奖项得主在过去一年赢得了客户的信任。这份认可将为未来数月医疗技术与服务领域的卓越合作树立标杆。”KLAS Research全球影像业务副总裁莫妮克·拉斯班德补充道：“阿格法医疗在多个企业影像细分领域的卓越表现，充分体现了客户的一致认可。医疗机构深知这类解决方案的价值——既能助力影像团队提升当下工作效率，又为未来的增长与创新铺就清晰路径。”“KLAS最佳”奖项基于医疗机构的直接反馈评选，旨在表彰那些通过合作伙伴关系、卓越表现及对客户需求的敏捷响应，持续展现卓越品质的供应商。阿格法医疗将在2026年HIMSS大会期间与客户及合作伙伴共同庆祝此次KLAS最佳奖项，以此践行其持续推进大规模互联、智能且以人为本的影像解决方案的承诺。KLAS参考资料最佳KLAS奖项概述：《2026最佳KLAS奖项：软件与服务报告》企业影像细分领域报告：《2026最佳KLAS奖项：软件与服务报告》关于爱格华医疗在爱格华医疗，我们深知临床效率与优质患者护理之间的关键平衡始于临床医生的体验。我们认识到临床医生全情投入病例、倾注全部精力做出自信而明智的诊断至关重要。正因如此，我们设计了企业影像平台，旨在消除阻碍这一目标的障碍。当干扰消弭，技术便成为思维的自然延伸，每位临床医生都能获得发挥专业精髓所需的一切。这便是“顺势而为”的真谛。这一理念贯穿我们所有行动——以使命宣言、愿景蓝图及客户交付原则为指引，致力于赋能临床工作者并提升其体验。爱克发医疗是爱克发集团旗下业务部门。如需了解更多关于爱克发医疗的信息，请访问 www.agfahealthcare.com 并关注我们的领英主页。AGFA及Agfa菱形标识均为比利时Agfa-Gevaert N.V.或其关联公司的注册商标。XERO为比利时Agfa HealthCare N.V.或其关联公司的注册商标。本文所含信息仅供参考，本出版物所述产品及服务的特性可随时变更，恕不另行通知。部分产品及服务可能无法在您所在地区提供。具体供应信息请咨询当地销售代表。AGFA HealthCare竭力确保信息准确性，但对任何印刷错误概不负责。关于KLAS研究KLAS研究是一家领先的医疗保健IT数据与洞察公司，致力于通过放大医疗服务提供者的声音来改善全球医疗服务。KLAS将于2026年迎来成立30周年，通过基于直接客户反馈的独立研究评估供应商表现。Best in KLAS®是KLAS研究的注册商标。媒体联络人：杰西卡·巴尔德里，爱克发医疗全球市场与传播经理电话：+44 1206 413052邮箱：jessica.baldry@agfa.com 来源：爱克发医疗 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 4, 2026) - Military Metals Corp. (CSE: MILI) (OTCQB: MILIF) (FSE: QN90) (the "Company" or "MILI") is pleased to report the additional analytical results of the Company's definition drilling campaign at the 100% owned flagship Trojárová Antimony-Gold Project (the "Project") in Slovakia as announced on November 4, 2025. The 2025 drilling campaign was designed to confirm historical drilling results and to support SLR Consulting's work towards establishing a current mineral resource estimate on the Project, which the company anticipates delivery of by the end of Q1, 2026, further discussed in the Company's January 9, 2025 announcement.These priority assay results represent the main mineralized zone from the third hole of the program, 25-TVA-003.Highlights of the Results from hole 25-TVA-003 Include:23.5 drilled (m) of 3.3 g/t Gold over a true width of 20.2m from 148.9m to 172.4mIncluding: 4.0m of 10.52 g/t Au over a true width of 3.4m from 157.9m to 161.9m1.9m of 2.53% Antimony over a true width of 1.6m from 169.9m to 171.8mScott Eldridge, Chief Executive Officer of the Company, commented, "We are thrilled with the second tranche of assays as we continue to see antimony grades that are consistent with historical results and higher than anticipated gold grades within the Trojárová Deposit. These strong gold results present the Company with new exploration opportunities that we are excited to evaluate. Trojárová represents the only antimony deposit in the European Union being advanced by modern mineral exploration and demonstrates characteristics that place it among the leading antimony projects globally. At a time when the need for secure, domestically sourced critical minerals is more pressing than ever, these results strengthen the project's potential importance to, and alignment with, the EU's objective of building a dependable, home-grown supply of essential raw materials."The Company additionally announces that logging and sampling of all drill core from the program is complete and all samples have successfully been delivered to ALS Laboratories in Roșia Montană, Romania for analysis. Additional results for all holes are pending.Table 1. Complete table of analytical results discussed in this release. Results exceeding 1.0 % Sb or 1.0 g/t Au are highlighted in red.Hole IDFrom (m)To (m)Drilledlength (m)True Width (m)Sample IDAntimony %Gold g/t25-TVA-003145.55146.50.950.813256260.016 0.01 146.5147.10.60.513256270.093 0.04 147.1148.110.863256280.123 0.52 148.1148.90.80.693256290.116 0.38 148.9149.910.863256311.145 1.1220.15m @ 3.3g/t True Width 149.9150.910.863256320.244 0.75 150.9151.910.863256330.057 0.7 151.9152.910.863256340.057 3.74 152.9153.910.863256360.279 4.5 153.9154.910.863256370.031 0.81 154.9155.910.863256380.189 1.05 155.9156.910.863256390.96 1.62 156.9157.910.863256410.807 1.3 157.9158.910.863256420.522 18.653.43m @ 10.52 g/tTrue Width158.9159.910.863256430.098 3.93159.9160.910.863256440.148 13.1160.9161.910.863256450.046 6.38161.9162.910.863256460.091 1.47 162.9163.910.863256470.169 0.76 163.9164.910.863256480.116 4.72 164.9165.910.863256490.088 1.76 165.9166.910.863256510.656 1.31 166.9167.910.863256520.307 1.37 167.9168.910.863256530.107 1.38 168.9169.910.863256540.247 1.19 169.9170.80.90.773256553.641.63m @ 2.53% True Width2.87 170.8171.810.863256561.542.66 171.8172.40.60.513256570.163 1.04 172.4173.410.863256580.136 0.08 173.4174.20.80.693256590.021 0.01 174.21750.80.693256610.582 0.35 17517610.863256621.57 0.71 17617710.863256630.097 2.01 177177.250.250.213256640.034 0.04 177.251780.750.643256660.507 0.34 17817910.863256670.103 0.24 17918010.863256680.261 0.62 18018110.863256690.1 0.54 181181.50.50.433256710.183 0.24 181.5182.510.863256720.018 0.01 182.5183.510.863256730.006 0.01 Figure 1. Gold mineralized drill core from hole 25-TVA-003 - 156.86m - 162.65m. Interval 157.9m to 161.9m yielded a composite grade of 10.52 g/t Au.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_002full.jpgFigure 2. Map of 2025 and Soviet era diamond drillholes in the north-central portion of Military Metals Trojárová Project.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/10818/282604_8fb84a54641daa6e_003full.jpgTable 2. Drillhole collar information for the Company's 2025 diamond drilling campaign at Trojárová. Locations presented are final and determined by a professional and qualified surveyor. WGS 84 / UTM Zone 33N DrillholeEastingNorthingElevation (m)Length (m)DipAzimuth25-TVA-0016626965358601640292.2-6522025-TVA-0026626855358668655289.7-7522025-TVA-0036625515358701634200.2-6522525-TVA-0046624755358809604256.5-5522525-TVA-0056623945358812580196-6023025-TVA-006662211535879556962.4-5722025-TVA-007662170535885255986.5-60210 Analytical and QA/QC ProceduresThe program was completed using PQ and HQ sized drill core. Sampled intervals were identified by logging geologists and assigned a unique sample identification number. Samples were split in two halves using a diamond bladed saw with one half remaining in the core box as a permanent record and the half placed in a plastic sample bag, both marked with a waterproof tag bearing the unique sample number which was also written on the sample bag in permanent marker. Samples were transported from the Company's secure facility by private courier to ALS Laboratories in Romania for geochemical analysis. ALS Laboratories is an independent ISO/IEC 17025:2017 and ISO 9001:2015 certified commercial laboratory with no relationship to the Company. The samples were analyzed using multi-element package ME_ICP41a and for gold using fire assay package Au-AA25. ME_ICP41a is an ore grade package involving digestion of a 0.4g sample by aqua regia with an Inductively coupled plasma - atomic emission spectrometry (ICP-AES) finish. The Au-AA25 fire assay method is an ore grade analysis using a 30g aliquot. The aliquot is mixed with flux composed of PbO and SiO2 with variable amounts of borax, soda ash and other reagents. The flux and sample are mixed, then heated at high temperature (>1,000°C) to decompose rock lattices and allow gold within the sample to be collected into a lead button. The button is placed in a porous cupel and heated again in an oxidizing environment to convert lead to lead oxide that is absorbed into the cupel, leaving the precious metals behind as a doré bead or prill. The gold content of the prill is then determined by atomic adsorption spectrometry.Both analyses are preceded by the preparation package Prep-31Y whereby the entire sample is crushed to 70% passing 2mm, a 250g split is collected by rotary splitter and pulverized to 85% passing 75 microns. Laboratory over-limits analysis methods were applied as required for both Sb and Au. A systematic QAQC protocol was employed that includes systematic insertion in the sample stream of certified reference materials and blank samples at a frequency of 1 in 10, plus analysis of duplicate pulp splits at a frequency of 1 in 30.About the Project and Historical ResourceDiscovered in the late 1970s, Trojárová was the focus of extensive surface and underground exploration over a 2km strike length from 1983 to 1995, with 63 core holes for a total of 14,330m, and 1.7km of underground workings completed. Efforts continued over the years as additional trenches were dug, and holes were drilled. Starting in 1990, underground development work began ultimately comprising a 300-meter-long adit connected to a 700-plus meter-long drive in the footwall of the mineralized zone with seven crosscuts into the mineralized zone for sampling purposes.These efforts culminated in a comprehensive study comprising drill logs, analyses, drill plans, maps and sections, deposit model studies, petrographic studies, metallurgical studies and more, now detailed in a multi-volume compendium of reports produced by the Slovak Geological Institute published in 1992, including a historical mineral resource estimate (see "Historical Resource Estimates" below). Per this historical estimate, at a cut-off grade of 1.0% antimony, Trojárová hosts 2.46 million tonnes averaging 2.47% antimony and 0.635 grams per tonne gold in a mineralized zone averaging 3.32 meters wide, containing approximately 60,000 tonnes of antimony in situ.Historical Resource EstimatesThe historical estimate related to the Trojárová Property was taken from a compendium produced by the Slovak Geological Survey, completed in March 1992 based on exploration work undertaking in the 1980s and 1990s. It is entitled (English translation): "FINAL JOB REPORT, PEZINOK-TROJAROVA, Geological Survey State Enterprise", report compendium number 78406 (Michel et al, 1992).The Slovak Geological Institute, the state agency that carried out all exploration and underground development work at Trojárová, classified the historical resources as "P1" and "C2" in the Slovak version of the Russian classification system, respectively. These are closest within the Canadian Institute of Mining, Metallurgy & Petroleum's ("CIM") classification system to "inferred mineral resources," which is defined by the CIM as that part of a mineral resource for which quantity and grade or quality are estimated on the basis of limited geological evidence gathered through appropriate sampling techniques from locations such as outcrops, trenches, pits, workings and drill holes.The historical work carried out appears comprehensive, detailed and at a professional standard. The Company considers this historical data to be relevant as the Company will use these data as a guide to plan future exploration programs. The Company also considers the data to be reliable for these purposes. A qualified person has not done sufficient work to classify the historical estimate as current, and the Company is not treating the historical estimate as current.Qualified PersonThe technical contents of this release were reviewed and approved by David Murray, P.Geo, VP-Exploration for Military Metals and a qualified person as defined by National Instrument 43-101.For more information about Military Metals Corp. and its critical minerals initiatives, please visit: https://www.militarymetalscorp.com.LinkedIn: https://www.linkedin.com/company/military-metals/X: https://x.com/militarymetalsFacebook: https://www.facebook.com/profile.php?id=61564717587797About Military Metals Corp. The Company is a British Columbia-based mineral exploration company that is primarily engaged in the acquisition, exploration and development of mineral properties with a focus on antimony.ON BEHALF OF THE BOARD of DIRECTORSFor more information, please contact:Scott EldridgeCEO and Directorscott@militarymetalscorp.com or info@militarymetalscorp.comFor enquiries, please call 604-537-7556Forward-Looking StatementsThis news release contains "forward-looking information". Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "intends", "anticipates", or "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this news release includes the timing of the mineral resource estimate being currently conducted, and its completion at all, future drilling and exploration work at Trojárová, the continuation of the value of antimony, and the future needs of Europe and the E.U. specifically. A variety of factors, including known and unknown risks, many of which are beyond our control, could cause actual results to differ materially from the forward-looking information in this news release. These include geopolitical developments related to the supply and value of antimony, the continued use of antimony and availability of alternatives, availability of capital and labour in respect of the property that is the subject of this news release, the results of any future exploration activities, which cannot be guaranteed, and any other future activities in respect of the property held by the Target. Additional risk factors can also be found in the Company's public filings under the Company's SEDAR+ profile at www.sedarplus.ca. Forward-looking statements contained herein are made as of the date of this news release and the Company disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or results or otherwise. There can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward looking statements if circumstances, management's estimates or opinions should change, except as required by securities legislation. Accordingly, the reader is cautioned not to place undue reliance on forward-looking statements.The Canadian Securities Exchange has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282604 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

BRUSSELS, BELGIUM, Feb 4, 2026 - (ACN Newswire via SeaPRwire.com) - Airwheel recently announced the continued rollout of its AI-driven rideable smart cabin suitcase solutions, marking a new phase in the evolution of intelligent travel mobility as global demand for smart transportation accelerates. Today, Airwheel’s sales and distribution network spans 68 countries and more than 4,600 retail locations worldwide. As its global expansion continues, the company’s electric and smart suitcases are transitioning from innovative products into high-frequency travel tools used by consumers around the world.Looking ahead, Airwheel will continue to advance the evolution of rideable smart luggage across technology, user experience, and application scenarios, allowing intelligent systems to integrate into travel in a more natural and intuitive way—so that travel becomes not just a means of transportation, but an opportunity to explore the world and enjoy life.As smart mobility continues to reshape global travel and transportation, intellectual property and design capability have emerged as key factors distinguishing true industry leaders from short-term innovators. In the field of rideable suitcase and smart mobility solutions, Airwheel has steadily strengthened its leadership position through long-term, systematic investment in technology and design.As one of the pioneers of the rideable smart luggage category, Airwheel has built a clear and robust competitive moat at the core technology level. To date, the company has accumulated more than 600 patents worldwide, covering critical areas such as motion control algorithms, electric drive systems, intelligent sensing, and structural design, including multiple international invention patents. In parallel, Airwheel has advanced its global intellectual property strategy, with trademarks registered in more than 168 countries and regions, providing a solid foundation for regulatory compliance, large-scale commercialization, and long-term brand development across international markets.Amid the rapid iteration of smart mobility products, design capability has become an equally important measure of product maturity. If patents represent technological depth and engineering strength, then international design awards serve as authoritative recognition of product philosophy, user experience, and comprehensive design excellence. In recent years, multiple Airwheel smart products have received recognition from leading global design awards, including the German iF Design Award, the U.S. IDEA Awards, the IAI Design Award, and the Berlin Design Award, demonstrating the brand’s consistent and high-level design output in the smart mobility space.These awards go far beyond aesthetics, evaluating products across dimensions such as usability logic, safety architecture, engineering integrity, human–machine interaction, and future application potential. Recognition from such professional juries indicates that Airwheel’s smart suitcase designs have been rigorously validated for both functional completeness and real-world usability, further enhancing the brand’s credibility in global markets.At the product level, the global popularity of the Airwheel SE3S Series marks a significant milestone in bringing rideable smart luggage into the mainstream. True product maturity is not defined solely by technical completeness, but by its ability to enter popular culture and everyday consumer awareness. Driven by social media and short-form video platforms, the Airwheel SE3S Series has become a favored electric suitcase among international celebrities, content creators, and fashion-forward travelers—often described as both a mobility tool and a “mobile lifestyle accessory.”Frequently seen in airports, fashion events, street photography, and travel scenarios, this rideable smart cabin suitcase not only serves a functional purpose but also delivers emotional value and personal expression. According to public data and platform analytics, content related to the Airwheel SE3S Series has generated tens of billions of impressions globally, transcending the boundaries of a single product category and becoming widely recognized as a fashionable travel symbol in the digital era.User feedback has further reinforced this dual identity. Many consumers describe the SE3S Series as “instantly recognizable” and “a travel companion that makes journeys lighter and more enjoyable,” strengthening its positioning at the intersection of smart mobility and lifestyle consumption.Notably, Airwheel has expanded its smart luggage ecosystem beyond adult users. The company also offers the SQ3 Series, a rideable smart suitcase designed specifically for children. By prioritizing safety and structural stability, the SQ3 Series introduces greater interaction and enjoyment into family travel, positioning smart luggage as an integral part of the parent-child travel experience.From a compliance perspective, the Airwheel SE3S Series is designed as a cabin suitcase, featuring a detachable lithium battery that meets airline safety standards, allowing it to be carried onboard flights in accordance with major international airline regulations. This design enables frequent, legal, and reliable use in airport environments worldwide, making it a practical choice for international travelers.Evolving from a mobility device into a source of emotional value and, ultimately, a widely recognized fashion travel product, the rise of the Airwheel SE3S Series signals that rideable smart luggage is becoming a natural part of everyday global travel.About AirwheelFounded in 2004, Airwheel is a global smart transportation device manufacturer with R&D, marketing, manufacturing, and logistics centers in the United States, Belgium, and China. The company has integrated the portable transportation industrial chain and built a globally recognized brand, serving more than 30 million users across 68 countries. Guided by its philosophy of “Free Intelligent Life,” Airwheel leverages technologies such as IoT sensors, robotics, and deep learning to develop intelligent mobility solutions that enhance freedom, joy, and everyday travel experiences worldwide.Media ContactCompany: AirwheelContact: Media TeamWebsite: https://www.airwheel.net Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

ROMEOVILLE, IL, Feb 2, 2026 - (ACN Newswire via SeaPRwire.com) - Formerra, a leader in performance materials distribution, today announced an expanded distribution agreement that brings Evonik's CARE brand healthcare grades into Formerra's medical portfolio. Covering the United States and Canada, the agreement creates new access points for high-performance polyamides used in essential healthcare applications.This expansion kicks off at MD&M West 2026 this week, and underscores both companies' commitment to supporting the healthcare market with high-performance materials, responsive service, and continuity of supply. It also builds on the companies' two-year partnership, which introduced Evonik's VESTAMID® and TROGAMID® families to Formerra's engineered materials lineup.With this expansion, Formerra will support Evonik healthcare grades designed for fluid handling, drug delivery, diagnostic systems, surgical instrument parts, medical device housings, components that see short-term body contact (< 30 days), and other non-implantable applications requiring strength, clarity, chemical resistance, and consistent processing.Key medical grade materials include:VESTAMID® Care ML PA12VESTAMID® Care ME PEBA elastomerTROGAMID® Care MX microcrystalline PA"Our healthcare customers rely on stable supply, world-class regulatory support, and materials that perform under demanding conditions," said Steve Harmon, Director, Key Accounts, Formerra. "Evonik's healthcare grades bring the combination of durability, processing consistency, and documentation support that medical manufacturers require. This expansion lets us strengthen the technical resources and materials pipeline available to teams developing next-generation devices.""Formerra's ability to serve the whole supply chain in the medical space, from design companies to compounders to medical device OEMs, with technical rigor and exceptional logistics and with already-proven successful demonstration in the industrial space, made this expansion with CARE brand Polyamide 12 products a natural step," said Basker Lalgudi, Business Manager, Global Medical Devices, Evonik. "Their healthcare expertise and focus help customers select and implement our materials with confidence across a range of critical applications."By adding Evonik's healthcare CARE brand materials, Formerra will offer customers a proven set of polyamide solutions that support regulatory pathways, design requirements, and long-term reliability. Formerra's team will provide material selection guidance, processing support, and regional supply chain readiness to help OEMs and molders accelerate development cycles.Formerra will exhibit at MD&M West in Booth 2266 in Anaheim, California, Feb. 3-5, 2026.Key Details:Formerra will distribute Evonik's CARE brand healthcare grades across the U.S. and Canada.Materials include healthcare grades within the VESTAMID® L, VESTAMID® E, and TROGAMID® CX families, plus designated sustainable options.The agreement strengthens Formerra's medical portfolio and expands its support for fluid management, diagnostics, wearables, and device housings.Formerra will provide application guidance, regulatory documentation support, and supply chain continuity for medical customers.About FormerraFormerra is a preeminent distributor of engineered materials, connecting the world's leading polymer producers with thousands of OEMs and brand owners across healthcare, consumer, industrial, and mobility markets. Powered by technical and commercial expertise, it brings a distinctive combination of portfolio depth, supply chain strength, industry knowledge, service, leading e-commerce capabilities, and ingenuity. The experienced Formerra team helps customers across multiple industries to design, select, process, and develop products in new and better ways, driving improved performance, productivity, reliability, and sustainability. To learn more, visit www.formerra.com.About EvonikEvonik goes beyond the boundaries of chemistry with its combination of innovative strength and leading technological expertise. The global chemical company, headquartered in Essen, Germany, is active in more than 100 countries and generated sales of €15.2 billion and earnings (adjusted EBITDA) of €2.1 billion in 2024. The common motivation of the approximately 32,000 employees: to provide customers with a decisive competitive advantage with tailor-made products and solutions as a superforce for industry, thereby improving people's lives. In all markets. Every day. To learn more, visit www.evonik.com.Media ContactJackie MorrisMarketing Communications Manager, Formerrajackie.morris@formerra.com+1 630-972-3144SOURCE: Formerra Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

Vancouver, British Columbia--(ACN Newswire via SeaPRwire.com - February 3, 2026) - Casa Minerals Inc. (TSXV: CASA) (OTCQB: CASXF) (FSE: 0CM) (the "Company" or "Casa"), is pleased to announce the closing of the first tranche of its previously announced non-brokered private placement (the "Offering"). The Company has closed on a total of 4,917,000 units (each, a "Unit") at a price of $0.125 per unit for gross proceeds of up to $614,625.00.Each Unit consists of one common share of the Company (a "Share") and one common share purchase warrant (each full warrant, a "Warrant"). Each of the 4,917,000 Warrants entitles the holder to acquire one additional share for a period of two years until February 04, 2028. The warrant exercise strike price is $0.15/share in the first three months and automatically converts to $0.20 per share then after for the remainder of the two years period.All issued Securities will be subject to a 4-month and one day hold-period, during which any resale or other transfer will be restricted in accordance with applicable securities laws.A Finder's Fees of $24,000 has been paid to registered financial institutions.Net proceeds from the offering will be used for general administration, exploration and development activities on the Company's projects in Arizona, and British Columbia, Canada. The Company will continue to raise the remaining placement in the coming week.The completion of the private placement remains subject to approval of the TSX Venture Exchange.None of the securities issued in the Offering will be registered under the United States Securities Act of 1933, as amended (the "1933 Act"), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act.About Casa Minerals Inc.The Company is engaged in the acquisition, exploration and development of mineral properties located in Canada and the USA. Casa owns ninety percent (90%) interest in the Congress gold mine (Arizona, USA). Additionally, the Company owns a one hundred percent (100%) interest in the polymetallic Pitman (BC, Canada) and has an option to acquire a seventy-five percent (75%) interest in the Arsenault VMS Property (BC, Canada).On Behalf of Board of Directors,Farshad Shirvani, M.Sc. GeologyPresident and CEOFor more information, please contact:Casa Minerals Inc.Farshad Shirvani, President & CEOPhone: (604) 678-9587Email: contact@casaminerals.comhttps://www.casaminerals.comNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/282620 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

香港, 2026年2月3日 - (亚太商讯 via SeaPRwire.com) - 近日，由上海实业（集团）有限公司（以下简称"上实集团"）与Azzurra Capital联合发起设立的亚洲环境科技合伙企业（Asia Environmental Technology Fund，简称"AETF"），已成功完成首关。AETF同步密集召开系列重要会议、深化多方合作对接，稳步推进落地运营与储备项目布局。作为上实集团与Azzurra Capital联手打造的专业绿色投资平台，AETF拟定目标规模为5亿美元。AETF将立足香港、面向全球，锚定绿色发展时代机遇，汇聚亚欧及中东优质资本支持，致力于成为跨境环境科技投资领域的标杆力量。依托"欧洲技术引进+亚洲企业出海"的双向跨境赋能模式，AETF将国际私募股权的专业投研能力与上实集团深厚的产业资源深度融合，紧扣全球ESG主题尤其是环境科技投资目标，充分借助亚洲工业基础与政策红利，精选具备高增长潜力的投资标的。通过双向赋能策略，既加速欧洲前沿环境技术在亚洲的场景落地，也助力亚洲绿色龙头企业迈向全球，兼顾成熟项目的稳健回报与早期科技项目的成长潜力，助力亚洲稳步迈向"碳达峰、碳中和"绿色未来。AETF将重点涵盖可再生能源产业链、能源转化和储能技术、赋能绿色低碳发展的数智化技术（AI、IoT及智能制造）、循环经济与资源再生、可持续农业与未来食品体系、气候科技（CCUS）及环境监测解决方案、具备全球出口竞争力的绿色消费品与可持续生活方式等领域。1月27日，AETF的GP公司召开首届董事会，凝聚合作共识、明晰推进路径、建立合规体系、储备重点项目、细化落实举措。在董事会召开期间，AETF董事和高管团队围绕落地运营、投资策略优化、多方合作拓展等召开了一系列专题会议，并同步拜访了香港多家知名机构，围绕环境健康领域潜在投资机遇、合作模式创新、跨境金融合规建设、项目协同联动、优质资源共享等议题深入交流讨论，为AETF精准对接香港本地优质资源、拓宽跨境合作版图筑牢根基。上实集团与Azzurra Capital将凭借各自独特优势，构建起优势互补、协同发展的良好合作格局。上实集团自1981年在香港成立以来，聚焦生命健康与环境健康两大核心赛道，在产业整合、项目运营、本地资源对接等方面积累了深厚底蕴与丰富经验。Azzurra Capital作为拥有成熟跨境基金管理经验的知名投资机构，资产管理规模近9亿美元，在欧洲、中东等地拥有广泛的优质资源与优秀的投资业绩，深耕绿色科技与可持续发展领域，专业能力获行业认可。双方携手发起设立AETF，既是响应全球低碳转型号召、践行绿色发展理念的重要举措，也是深化跨境投资合作、支持沪港协同发展，赋能亚洲环境科技产业高质量发展的具体实践，更是双方实现优势互补、合作共赢的战略抉择。香港当前正在全力发展创科、绿色金融等新引擎，通过扮演更积极的"超级联系人"和"超级增值人"角色，在服务国家大局中实现自身的高质量发展。作为上实集团在港开展金融投资业务的平台，上实资本（香港）本次与Azzurra Capital合作携手发起设立AETF，是上实资本（香港）紧抓当前香港发展机遇，服务在港发展，充分激发"香港所长"与"上海所能"的互补势能，系统推动两地创新链、产业链、资金链与人才链的深度融合的具体实践，将为加快构建开放融合、链接全球的创新生态系统，为沪港国际科技创新中心建设提供支撑。上实集团首席金融投资官谷峰先生表示，此次与Azzurra Capital的合作，是上实集团将深厚产业资源与全球资本及顶尖投资管理经验深度融合的重要战略举措。期待通过AETF这一平台，不仅投资技术，更致力于培育产业。我们将积极开放自身的应用场景与生态系统，为优秀的绿色科技企业提供从验证到规模化发展的全方位支持，共同推动亚太区域的绿色转型与高质量发展。Azzurra Capital创始合伙人Stefano Eugenio Marsaglia指出，亚洲作为全球低碳转型的核心阵地，拥有巨大的投资潜力与广阔的发展空间，绿色发展已成为不可逆转的时代潮流。AETF的成功设立，搭建起了连接欧洲、中东与亚洲绿色投资市场的重要桥梁，未来将充分发挥双方专业优势，推动先进技术、优质资本与广阔市场的跨境流动，全力打造亚洲环境科技投资领域的标杆，为全球低碳转型贡献力量。风劲潮涌正当时，扬帆奋进启新程。AETF将以此次首关为重要契机，加速推进后续扩募进程，聚焦核心投资领域精准发力、推进优质项目落地见效，持续深化与各方机构的合作对接，积极开展品牌建设与行业交流。AETF将始终以"欧洲技术引进+亚洲企业出海"双向策略为核心，持续作为双方跨境绿色合作的核心载体，在各类行业峰会中传递合作价值、链接优质资源。AETF将以资本为纽带、以创新为动力，赋能亚洲环境科技产业高质量发展，推动ESG投资理念深度落地，为全球低碳转型注入持久动能、贡献坚实力量。 Copyright 2026 亚太商讯 via SeaPRwire.com. All rights reserved. www.acnnewswire.com